ABVX Abivax S.A.
- 13.580
- -0.040-0.29%
- 13.820
- +0.240+1.77%
Abivax S.A. News
Abivax S.A. | 6-K: Report of foreign private issuer (related to financial reporting)
Abivax Releases the Results of Its May 30, 2024 Ordinary and Extraordinary General Meeting
PARIS, France, June 4, 2024 – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural
Express News | Abivax SA : Btig Initiates Coverage With Buy Rating; Price Target $43
BTIG Initiates Coverage On Abivax With Buy Rating, Announces Price Target of $43
BTIG analyst Julian Harrison initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and announces Price Target of $43.
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model at Digestive Disease Week 2024
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST – Abivax SA
Abivax Annual Ordinary and Extraordinary General Meeting of May 30, 2024 - Availability of the Preparatory Documents
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 Availability of the preparatory documents PARIS, France, May 7, 2024, 10:00PM CEST – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or
Express News | Abivax Shares Are Trading Higher After Guggenheim and Piper Sandler Initiated Coverage on the Stock With Bullish Ratings
Express News | Guggenheim Initiates Coverage On Abivax With Buy Rating, Announces Price Target of $50
Express News | Abivax SA : Piper Sandler Initiates Coverage With Overweight Rating; Target Price $42
Express News | Abivax : Morgan Stanley Raises Target Price to $16.00 From $15.00
Abivax Publishes Financial Reports With the French and U.S. Securities Regulatory Agencies
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a
Earnings Scheduled For April 2, 2024
Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter. • Allego (NYSE:ALLG) is projected to report quarterly loss at $0.04 per share on reve
Express News | Abivax FY23 Net Loss €(147.4)M Down From €(60.7)M YoY; Cash Position €261M
Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor
Sofinnova Investments, a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor. In this role, he will be advising Sofinnova's portfolio companies on
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics th
Abivax Appoints Ana Sharma as Vice President, Global Head of Quality
Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused
Abivax Announces Update to Obefazimod Phase 2b Clinical Development Program in Moderately to Severely Active Crohn's Disease
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease Obefazimod Crohn's Disease (CD) IND filed with the FDA in December 2023 and cleared to
Express News | Abivax To Host KOL Investor Event To Review Phase 2B Data And Phase 3 Trial Design For Obefazimod In Patients With Moderately To Severely Active Ulcerative Colitis On February 6
Abivax to Host KOL Investor Event to Review Phase 2b Clinical Data and Phase 3 Trial Design for Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis on February 6, 2024
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS, France, January
Abivax Sets 2024 Strategic Vision With Major Milestones, Prioritizes Completion Of Patient Recruitment Into The ABTECT Phase 3 Induction Trials
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 monthsInduction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in moderate
Analysis
Price Target
No Data
